Aralez Pharmaceuticals Inc.
http://aralez.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Aralez Pharmaceuticals Inc.
Lilly Adds To Radiopharma Arsenal With Option To Buy Radionetics
Lilly paid $140m up front for an option to acquire Radionetics for $1bn within an undisclosed timeframe. The private firm is developing small molecule GPCR-targeted radiopharmaceuticals.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
Crinetics May Have Drug Profile To Take Leading Position In Acromegaly
Reporting a second positive Phase III trial for oral paltusotine, Crinetics plans an NDA later this year to position its drug against competing injectable somatostatin analogs.
Finance Watch: Denali, Avidity And Others Chase Big Money Via Private Placements
Public Company Edition: Denali, Crinetics and Ocular Therapeutix grossed $500m, $350m and $325m, respectively, in private placements ahead of data readouts. Also, Viking raised $550m after its positive Phase II obesity data and Abingworth invested $210m in Gilead’s Trodelvy NSCLC trials.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Medical Futures Inc.
- POZEN Inc.
- Stellar Pharmaceuticals, Inc. (SLXCF)
- Tribute Pharmaceuticals Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice